Pain Management · AnalgesicsRegulatory Approvalregulatorymid-term

FDA Approval Status Update for Acetaminophen and Codeine Phosphate

Importance6/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/28/2026, 12:32:22 AM

Assessment confidence: 44% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The FDA's approval of SPECGX LLC's ANDA040419 application for Acetaminophen and Codeine Phosphate is significant as it may strengthen their market position in the competitive pain management sector. Pharma companies should closely monitor this development for potential impacts on market dynamics and pricing strategies. Regulatory context from FDA (FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)) supports the near-term read. Assessment grounded in 13 ranked evidence items (1 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this approval on market share and pricing strategies for competing analgesics. The strongest clinical anchor is Evaluation of the Japet.W+ Medical Device for Low Back Pain Management (ClinicalTrials.gov), sub-indication match (pain). In pain, 8 regulatory and 3 competitive items passed relevance filtering for SPECGX LLC.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approval for Oxycodone Hydrochloride by Novel Labs (Humanexa Signals) — sub-indication match (pain). Secondary pressure from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. This approval may enhance SPECGX LLC's position in the pain management market, potentially impacting competitors with similar analgesic products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL) (FDA). Entity match (specgx llc); Regulatory pathway relevance (nda). The AP status indicates a favorable regulatory outcome, but companies must remain vigilant regarding compliance and any subsequent regulatory changes that may arise.

Key Risks

Elevated medium regulatory exposure for SPECGX LLC could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

This approval could lead to increased market share for SPECGX LLC, potentially affecting the revenue and competitive positioning of other companies with similar analgesic products.
Portfolio teams should assess the implications of this approval on market share and pricing strategies for competing analgesics.

What Would Change This Assessment

This becomes more urgent if Monitor for further developments regarding market launch and any competitive responses from other analgesic manufacturers.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
Outcome from FDA Approval for Oxycodone Hydrochloride by Novel Labs would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)
FDAmedium relevance
Entity match (specgx llc); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)
FDAmedium relevance
Entity match (acetaminophen and codeine phosphate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)
FDAmedium relevance
Entity match (acetaminophen and codeine phosphate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)
FDAmedium relevance
Entity match (acetaminophen and codeine phosphate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source

Evaluation of the Japet.W+ Medical Device for Low Back Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View source
Effects of Music Therapy in Chronic Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparative Outcomes of Inj Botox Alone vs Inj Botox Combined With Fissurectomy and Anoplasty in the Management of Chronic Anal Fissure
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparison of HF10 Therapy Combined With CMM to CMM Alone in the Treatment of Non-Surgical Refractory Back Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Outcome of Treatment With Botulinum toxinA in Patients With Temporomandibular Myofascial Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Approval for Oxycodone Hydrochloride by Novel Labs
Humanexa Signalsmedium relevance
Sub-indication match (pain)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)

Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

SPECGX LLC
acetaminophen and codeine phosphate

Commercial impact

medium

This approval could lead to increased market share for SPECGX LLC, potentially affecting the revenue and competitive positioning of other companies with similar analgesic products.

Regulatory impact

medium

The AP status indicates a favorable regulatory outcome, but companies must remain vigilant regarding compliance and any subsequent regulatory changes that may arise.

What to watch

Monitor for further developments regarding market launch and any competitive responses from other analgesic manufacturers.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.